TLDR Combining Ficlatuzumab and Gefitinib can cause severe hair loss.
The document reported a case of severe refractory scarring alopecia linked to the combined use of Ficlatuzumab (AV-299) and Gefitinib. The authors, Yi-Hsien Shih, Pin-Chun Chen, and Chia-Yu Chu, highlighted the potential adverse effects of this drug combination, emphasizing the need for careful monitoring in patients undergoing such treatments. The study underscored the importance of recognizing drug-induced alopecia as a significant side effect, which could impact patient quality of life and treatment adherence.
25 citations
,
April 2010 in “Clinical and Experimental Dermatology” Erlotinib can cause hair loss and scalp issues, which improve after stopping the drug.
73 citations
,
November 2000 in “Proceedings of the National Academy of Sciences of the United States of America” There are two ways to start hair growth: one needs Stat3 and the other does not, but both need PI3K activation.
7 citations
,
January 2023 in “Anti-Cancer Drugs” Early diagnosis and treatment of EGFR inhibitor-induced folliculitis decalvans can prevent permanent hair loss.
1 citations
,
December 2012 in “Journal of dermatological science” Combining ficlatuzumab and gefitinib can cause severe scarring hair loss.
179 citations
,
June 2000 in “The American journal of pathology” The absence of functional sebaceous glands causes hair follicle destruction and scarring alopecia.
54 citations
,
January 2009 in “British Journal of Dermatology” Scarring alopecia affects different hair follicle stem cells than nonscarring alopecia, and the infundibular region could be a new treatment target.
37 citations
,
June 2011 in “Journal of The American Academy of Dermatology” Loss of sebaceous glands and inflammation may contribute to the development of scarring alopecia.
